StockNews.com Initiates Coverage on Senseonics (NYSE:SENS)

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Stock Performance

Shares of NYSE SENS opened at $0.31 on Monday. The firm’s 50-day moving average price is $0.33 and its 200-day moving average price is $0.38. Senseonics has a 52-week low of $0.28 and a 52-week high of $0.75. The company has a market cap of $185.38 million, a PE ratio of -2.40 and a beta of 0.79. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Institutional Trading of Senseonics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC raised its stake in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after buying an additional 167,970 shares during the period. GSA Capital Partners LLP bought a new stake in Senseonics during the 3rd quarter worth approximately $117,000. Virtu Financial LLC purchased a new position in Senseonics during the first quarter valued at approximately $162,000. Symmetry Partners LLC bought a new position in shares of Senseonics in the third quarter worth approximately $164,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. 12.36% of the stock is owned by hedge funds and other institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.